Teva Pharmaceutical Indus Analyst Price Targets

Ganancias: Beneficios de Q3 2026 dentro de 7 días de ahora en mar nov 3rd, antes de la apertura del mercado

Conferencia telefónica: Conferencia telefónica programada para dentro de 7 días a las 8:00 a. m.

Fusiones y adquisiciones: BioXcel Therapeutics (BTAI) sold assets to Teva Pharmaceutical Indus (TEVA) on Tuesday, October 27, 2026

Teva Pharmaceutical Indus Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teva Pharmaceutical Indus (TEVA).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$40Upside to Avg. PT+0.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$42→$47
Oct 12, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$40→$50
Oct 1, 2026	TD Cowen	Joseph Thome	Initiate	Buy	$55
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$50
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$45
Sep 4, 2026	UBS	Ashwani Verma	PT Raise	Buy	$42→$48
Aug 12, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$40→$42
Jul 28, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$44
May 6, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$38→$40
Apr 30, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$42→$45
Apr 30, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$41→$42
Apr 30, 2026	UBS	Ashwani Verma	PT Raise	Buy	$36→$42
Apr 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$35→$40
Apr 9, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$38→$42
Mar 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$40→$41
Feb 18, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$38→$42
Feb 9, 2026	Goldman Sachs	Matt Dellatorre	PT Raise	Buy	$36→$45
Jan 30, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$35→$38
Jan 29, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$36→$38
Jan 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$35→$40

Analyst Ratings News

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.

Benzinga Newsdesk

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.

Avi Kapoor

PRO
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55

TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $55.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.

Benzinga Newsdesk

Teva Pharmaceutical Industries Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL